The platform uses edge AI and low-power technology to monitor heart health, detect issues, send alerts, and support continuous data tracking in various settings.

Ambiq has partnered with CardioMedive to develop the Medive platform, a modular health monitoring system powered by Ambiq’s Apollo510 microcontroller. The collaboration focuses on delivering solutions for cardiovascular care using edge AI technology.
The microcontroller uses Ambiq’s Subthreshold Power Optimised Technology (SPOT) to achieve energy efficiency while supporting edge AI processing. This allows the Medive platform to operate with low power consumption. The Medive system is designed with a modular architecture that supports various patient monitoring tools in a single platform. It integrates a 1-lead multi-parameter patch, 3/5/12-lead ECGs, blood pressure monitoring, SpO₂, temperature, respiration tracking, a digital stethoscope, and remote examination functions.
The system supports extended battery operation to allow continuous data collection. Its design enables collecting health data over several weeks without frequent charging or replacement. Dual SDIO interfaces in the microcontroller enable simultaneous Wi-Fi and eMMC storage operation. This supports data transfer and storage without affecting system performance.
The Medive platform uses AI-based analytics to provide cardiovascular insights in various environments, including clinics and homes. The microcontroller’s edge computing capabilities for on-device inferencing support the detection of anomalies, patient alerts, and monitoring based on patterns. This reduces reliance on cloud processing and lowers latency. The Apollo510’s dual SDIO architecture allows the Medive to use Wi-Fi and eMMC storage simultaneously, supporting data transfer and connectivity without performance loss.
“CardioMedive is transforming all phases of the patient’s journey for both in-home and hospital care,” says Fumihide Esaka, CEO of Ambiq. “We are proud to power such an important digital health innovation that makes effective prevention, diagnosis, and disease management more accessible using our ultra-low power solutions.”
Ion Mocanu, CEO & Co-founder of CardioMedive, added, “Our partnership with Ambiq has been instrumental in creating a groundbreaking platform that addresses critical healthcare challenges. The Apollo510’s exceptional processing power, peripherals and energy efficiency have enabled us to design a solution that meets today’s needs and is future-proofed for tomorrow’s healthcare innovations.”